Biomind Labs Inc. (BMNDF)
USD 0.7
(150.27%)
USD 0.7
(150.27%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1 Million USD | 64.18% |
| 2022 | -2.81 Million USD | 17.04% |
| 2021 | -3.39 Million USD | -1687.8% |
| 2020 | -190.03 Thousand USD | 32.04% |
| 2019 | -279.62 Thousand USD | 82.41% |
| 2018 | -1.58 Million USD | -1.96% |
| 2017 | -1.55 Million USD | -86.96% |
| 2016 | -833.95 Thousand USD | 46.84% |
| 2015 | -1.56 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -110.17 Thousand USD | -16.05% |
| 2024 Q2 | -108.51 Thousand USD | 3.51% |
| 2023 Q2 | -364.22 Thousand USD | 11.37% |
| 2023 Q3 | -126.99 Thousand USD | 65.13% |
| 2023 Q4 | -94.93 Thousand USD | 25.25% |
| 2023 Q1 | -410.95 Thousand USD | 21.87% |
| 2023 FY | -1 Million USD | 64.18% |
| 2022 Q1 | -732.81 Thousand USD | 37.77% |
| 2022 FY | -2.81 Million USD | 17.04% |
| 2022 Q4 | -525.98 Thousand USD | 38.19% |
| 2022 Q3 | -850.96 Thousand USD | -10.01% |
| 2022 Q2 | -773.51 Thousand USD | -5.55% |
| 2021 Q1 | -50.45 Thousand USD | 0.0% |
| 2021 Q4 | -1.17 Million USD | 29.05% |
| 2021 Q2 | -183.23 Thousand USD | -263.19% |
| 2021 Q3 | -1.65 Million USD | -805.7% |
| 2021 FY | -3.39 Million USD | -1687.8% |
| 2020 Q1 | -63.11 Thousand USD | 0.0% |
| 2020 FY | -190.03 Thousand USD | 32.04% |
| 2019 FY | -279.62 Thousand USD | 82.41% |
| 2018 FY | -1.58 Million USD | -1.96% |
| 2017 FY | -1.55 Million USD | -86.96% |
| 2016 FY | -833.95 Thousand USD | 46.84% |
| 2015 FY | -1.56 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 24.399% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 79.986% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 94.343% |
| Nascent Biotech, Inc. | -2.22 Million USD | 54.724% |
| Rebus Holdings, Inc. | -664 Thousand USD | -52.049% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.233% |
| Qrons Inc. | -643.67 Thousand USD | -56.849% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -159.158% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 98.181% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -142.997% |
| Skye Bioscience, Inc. | -13.67 Million USD | 92.615% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.594% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 120.542% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -285.748% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.669% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 64.582% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 34.273% |
| Mesoblast Limited | -84.14 Million USD | 98.8% |
| Marizyme, Inc. | -34.08 Million USD | 97.038% |
| Genus plc | 6.4 Million USD | 115.775% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 110.363% |
| Pharming Group N.V. | -4.87 Million USD | 79.309% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 49.176% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -8.399% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 87.909% |
| ContraFect Corporation | -56.88 Million USD | 98.225% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 77.834% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 27.988% |
| IMV Inc. | -38.67 Million USD | 97.389% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 63.298% |
| MultiCell Technologies, Inc. | -722.81 USD | -139577.509% |
| ONE Bio Corp. | 13.68 Million USD | 107.379% |
| Accustem Sciences Inc. | -3.74 Million USD | 73.052% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 98.289% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -109.001% |
| Q BioMed Inc. | -3.44 Million USD | 70.699% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 128.52% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 61.576% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 98.163% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 65.201% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 84.813% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 45.847% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -3270.737% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 93.638% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 47.76% |
| GB Sciences, Inc. | -1.42 Million USD | 28.927% |
| Alpha Cognition Inc. | -9.7 Million USD | 89.598% |
| HST Global, Inc. | -140.9 Thousand USD | -616.503% |
| CSL Limited | 3.7 Billion USD | 100.027% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 10.25% |
| Halberd Corporation | -75.05 Thousand USD | -1245.241% |
| Enzolytics Inc. | -2.14 Million USD | 53.015% |
| Agentix Corp. | -1.37 Million USD | 26.401% |
| Resverlogix Corp. | -12.74 Million USD | 92.081% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 68.134% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.762% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 3.295% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 65.418% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 36.075% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 70.349% |
| AVAX Technologies, Inc. | 6.69 Million USD | 115.085% |
| Zenith Capital Corp. | -8.94 Million USD | 88.711% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.757% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5695.322% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 58.881% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -488.657% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 49.64% |
| Kadimastem Ltd | -3.04 Million USD | 66.792% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -2.596% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 19.618% |
| BioStem Technologies, Inc. | -7.77 Million USD | 87.021% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -456.301% |
| LadRx Corporation | -3.82 Million USD | 73.596% |
| Cell Source, Inc. | -4.32 Million USD | 76.658% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -46.969% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -46.969% |
| NovAccess Global Inc. | -2.46 Million USD | 59.072% |
| Affymax, Inc. | -15.04 Million USD | 93.29% |
| Itoco Inc. | -919.14 Thousand USD | -9.842% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 76.18% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 9.776% |
| Mobile Lads Corp. | -554.55 Thousand USD | -82.058% |
| CytoDyn Inc. | -18.05 Million USD | 94.409% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -3911.136% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -358.748% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -78.778% |
| SYBLEU INC | -149.18 Thousand USD | -576.768% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 44.415% |
| International Stem Cell Corporation | -663 Thousand USD | -52.278% |
| Bioxytran, Inc. | -3.82 Million USD | 73.572% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1817.939% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -4863.633% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 97.216% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 37.602% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -37.205% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 67.547% |
| Neutra Corp. | -229.48 Thousand USD | -339.941% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 94.244% |
| PureTech Health plc | -146.19 Million USD | 99.309% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 95.302% |
| IXICO plc | -1.43 Million USD | 29.742% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 89.363% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.171% |
| CSL Limited | 3.81 Billion USD | 100.026% |
| Cellectis S.A. | -108.85 Million USD | 99.073% |